共 43 条
[1]
Tannock IF(1996)Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1756-1764
[2]
Kantoff PW(1999)Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 2506-2513
[3]
Petrylak DP(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-1520
[4]
Tannock IF(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1512
[5]
Liu G(1997)Patient preferences for oral J Clin Oncol 15 110-115
[6]
Franssen E(2002) intravenous palliative chemotherapy Eur J Cancer 38 349-358
[7]
Fitch MI(2001)Patient preference and pharmacokinetics of oral modulated UFT J Clin Oncol 19 44-53
[8]
Warner E(1993) intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer Cancer 72 1965-1968
[9]
Borner MM(1994)Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer Ann Oncol 5 644-645
[10]
Kelly WK(1996)A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study Am J Clin Oncol 19 23-25